(redirected from chronic lymphocytic leukemia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.


Fifth letter of a Nasdaq stock symbol specifying that it is the third preferred bond of the company.


1. On a stock transaction table, a symbol indicating that a dividend was paid after a stock split.

2. A symbol appearing next to a bond listed on NASDAQ indicating that the bond is a company's third preferred bond. All NASDAQ listings use a four-letter abbreviation; if the letter "I" follows the abbreviation, this indicates that the security being traded is a third preferred bond.


Used in the dividend column of stock transaction tables to indicate that the dividend was paid after a stock dividend or split: Lehigh s.20i.
Mentioned in ?
References in periodicals archive ?
The report reviews key players involved Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects
The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
The company said the randomized, multi-centre, open-label Phase III RESONATETM-2 (PCYC-1115) trial assessed the use of IMBRUVICA (ibrutinib) versus chlorambucil in treatment-naive chronic lymphocytic leukemia (CLL) patients aged 65 years or older.
The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
This year, it is expected that there will be approximately 5,000 deaths from Chronic Lymphocytic Leukemia in the United States.
Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016', provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

Full browser ?